Loading
The science, the approved products, the supply bottleneck, and the alpha-emitter pipeline that drives the M&A.
A molecule that homes to the tumour carries a radioactive atom. The same molecule with a different atom lets you see the tumour first.
Why here The front and its constraint: isotope supply.
Using the same targeting molecule for a diagnostic scan and a therapy, so you treat exactly what you can see.
Why here The see-then-treat paradigm in one term.
A prostate-cancer-specific PET scan that finds spread far earlier than CT or bone scan, and tells you whether a matched radioactive drug will work.
Why here The gatekeeper scan that defines the treatable population.
A radioactive drug that seeks out PSMA on prostate cancer cells; the best-selling radiopharmaceutical ever.
Why here The best-selling radiopharmaceutical and its label history.
A drug that finds tumour cells and carries a radioactive atom that irradiates them from inside the body.
Why here How beta emitters work and their limits.
Beta particles (lutetium-177) travel millimetres and are good for bulky disease; alpha particles (actinium-225) travel a few cells' width and kill with far higher energy.
Why here Why actinium is the prize.
Like radioligand therapy but with alpha particles: far more destructive over a much shorter range, so single cells can be killed with less collateral damage.
Why here The phase 3 alpha programmes and the supply problem.
Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility to raise supply 20-fold.
Why here Who is scaling actinium-225.
FAP (fibroblast activation protein) sits on the cancer-associated fibroblasts that scaffold more than 90% of epithelial cancers and is almost absent from normal adult tissue. FAPI PET tracers therefore light up tumours with high contrast, including pancreatic, gastric and low-grade cancers where FDG PET is weak, and FAP-targeted radioligands are in development.
Why here The pan-cancer stromal target that could widen the market.
After lutetium therapy stops working, an actinium version of the same drug can still produce responses.
Why here The sequencing thesis.
The radiopharmaceutical roadmap runs eighty years from radioactive iodine for thyroid cancer to alpha-emitting drugs for prostate and neuroendocrine cancers, with isotope supply as the limiting factor.
Why here The whole arc, historic to speculative.